Clinical trials: Neuropsychiatric Disorders
Alzheimer Disease, Mild Memory Disturbance
The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study
The purpose of this research study is to learn whether it is possible and useful for caregivers to report behavioral or psychological symptoms of people with mild memory problems or Alzheimer's disease through a smartphone mobile…
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Trial name
- MOMENT (NCT04482036)
- Testing
- Mobile Phone Application Assessments, Standard Assessments
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indiana University
Pain, Dementia
Music Based Caregiving in Patients With Pain and Dementia
The main objective of this study is to evaluate the pain-relieving effect of a well-characterized non-pharmacological treatment program, music-based caregiving (MBC), to patients in nursing homes with dementia and pain.
- Conditions
- Pain, Dementia, Music, Activity, Motor
- Trial name
- NCT04229446
- Testing
- Music based caregiving
- Where
- 2 sites in Norway
- Volunteers
- 276 people
- Sponsor
- Oslo University Hospital
Agitation, Alzheimer's Disease
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with Alzheimer's Disease (AD).
- Trial name
- NCT01584440
- Testing
- AVP-923-20, AVP-923-30
- Where
- 44 sites in United States
- Volunteers
- 220 people
- Sponsor
- Avanir Pharmaceuticals
Dementia With Lewy Bodies
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
This research study is to examine the effects of the study medication Armodafinil in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT01023672
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Dementia
Tailored Activity Program-Veterans Affairs
The Tailored Activity Program - Veterans Administration is a Phase III efficacy trial designed to reduce behavioral symptoms in Veterans with dementia living with their caregivers in the community.
- Trial name
- NCT01357564
- Testing
- Tailored Activity Program, Attention Control
- Where
- United States
- Volunteers
- 322 people
- Sponsor
- VA Office of Research and Development
Dementia With Lewy Bodies
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
This study will be conducted to compare Irsenontrine to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus…
- Trial name
- NCT03467152
- Testing
- Irsenontrine
- Where
- 74 sites in United States, France and 5 more
- Volunteers
- 326 people
- Sponsor
- Eisai Inc.
PANDAS, Anxiety Disorder
Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children.
- Conditions
- PANDAS, Anxiety Disorder, Autoimmune Diseases, Obsessive-Compulsive Disorder
- Trial name
- NCT04015596
- Testing
- Naproxen Sodium
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Phenylketonuria
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
- Trial name
- NCT01114737
- Testing
- Sapropterin dihydrochloride
- Where
- 36 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- BioMarin Pharmaceutical
Smoking Cessation
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric…
- Trial name
- EAGLES (NCT01456936)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 156 sites in United States, Argentina and 14 more
- Volunteers
- 8,144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Parkinson's Disease
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
This is a pilot study to explore the effects of pimavanserin and low-dose quetiapine in subjects with Parkinson's disease with neuropsychiatric symptoms.
- Trial name
- NCT04164758
- Testing
- Pimavanserin, Quetiapine
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Obsessive-Compulsive Disorder, Children
Intravenous Immunoglobulin for PANDAS
Background: Some children experience a sudden onset of symptoms similar to those found in obsessive-compulsive disorder that may be caused by the body s reaction to an infection with streptococcal bacteria, most commonly seen as…
- Conditions
- Obsessive-Compulsive Disorder, Children, Anxiety Disorder, Autoimmune Disease
- Trial name
- NCT01281969
- Testing
- Gamunex Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer's Disease
Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease of aging. Neuropsychiatric symptoms (NPS) in AD are a major cause of burden to patients, caregivers, and society and are near-universal at some point in the…
- Trial name
- THC-AD (NCT02792257)
- Testing
- Dronabinol (Marinol®)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Johns Hopkins University
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin…
- Trial name
- NCT03623321
- Testing
- Pimavanserin
- Where
- 88 sites in United States, Bulgaria and 10 more
- Volunteers
- 595 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer's Disease, Agitation
Citalopram for Agitation in Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
- Trial name
- CitAD (NCT00898807)
- Testing
- citalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- JHSPH Center for Clinical Trials
Alzheimer's Disease
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's disease.
- Trial name
- NCT00843518
- Testing
- LY451395
- Where
- 17 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
- Trial name
- NCT03575052
- Testing
- Pimavanserin
- Where
- 104 sites in United States, Bulgaria and 10 more
- Volunteers
- 784 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Dementia, Depression
Pilot Study to Examine Health Effects of Daylight Exposure on Dementia Patients
This study is designed to test the hypothesis that an intervention increasing exposure to daylight indoors will reduce depression and other neuropsychiatric symptoms among people living with dementia in long term care facilities.
- Conditions
- Dementia, Depression, Behavior Disorders
- Trial name
- NCT03483896
- Testing
- Daylight Intervention
- Where
- 8 sites in United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Dementia, Alzheimer Disease
The Healthy Patterns Sleep Study
The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia.
- Conditions
- Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder
- Trial name
- NCT03682185
- Testing
- Attention-Control Condition, Timed Activity Intervention
- Where
- United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infection, HIV
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
The purpose of this study is to compare the neuropsychiatric adverse event profiles of etravirine 400mg once daily versus efavirenz 600mg once daily, in combination with 2 N(t)RTIs, in approximately 150 treatment-naÃ-ve HIV-1…
- Conditions
- HIV Infection, HIV, Acquired Immunodeficiency Syndrome
- Trial name
- SENSE (NCT00903682)
- Testing
- etravirine (ETR, TMC125), efavirenz (EFV)
- Where
- 33 sites in Austria, Denmark and 9 more
- Volunteers
- 157 people
- Sponsor
- Janssen-Cilag International NV
Alzheimer's Disease
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
This study will evaluate safety and efficacy of PF-05212377 in subjects with mild-to-moderate Alzheimer's Disease with existing neuropsychiatric symptoms on a stable dose of Donepezil.
- Trial name
- NCT01712074
- Testing
- PF-05212377 (SAM-760)
- Where
- 60 sites in United States, Canada and 5 more
- Volunteers
- 186 people
- Sponsor
- Pfizer